世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

微小残存病変(MRD)検査市場:技術別(フローサイトメトリー、ポリメラーゼ連鎖反応(PCR)、次世代シーケンス(NGS)、その他)、用途別(血液悪性腫瘍、固形腫瘍)、エンドユーザー別(病院・専門クリニック、診断研究所、学術・研究機関、その他)、地域別 2024-2032


Minimal Residual Disease (MRD) Testing Market by Technology (Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), and Others), Application (Hematological Malignancy, Solid Tumors), End User (Hospitals and Speciality Clinics, Diagnostic Laboratories, Academic and Research Institutes, and Others), and Region 2024-2032

世界の微小残存病変(MRD)検査市場規模は2023年に21億米ドルに達した。今後、IMARC Groupは、2024年から2032年にかけて10.21%の成長率(CAGR)を示し、2032年までに51億米ドルに達すると予測している。ヘルスケ... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
IMARC Services Private Limited.
アイマークサービス
2024年1月30日 US$3,899
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
141 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

世界の微小残存病変(MRD)検査市場規模は2023年に21億米ドルに達した。今後、IMARC Groupは、2024年から2032年にかけて10.21%の成長率(CAGR)を示し、2032年までに51億米ドルに達すると予測している。ヘルスケア産業の著しい成長、広範な研究開発(R&D)活動、急速な技術進歩は、市場を牽引する重要な要因のひとつである。

微小残存病変(MRD)検査は、がん治療後に患者の体内に残存する可能性のある少量のがん細胞を検出・監視するために用いられる医療検査である。MRD検査は、白血病、リンパ腫、多発性骨髄腫、一部の固形がんなど、さまざまな種類のがんの検査に広く用いられている。MRD検査では、サイトメトリー、ポリメラーゼ連鎖反応(PCR)、次世代シークエンシング(NGS)など、感度の高い方法が用いられる。MRD検査は、がん患者をモニタリングし、医師が十分な情報を得た上で治療方針を決定するための重要な医療検査です。MRD検査は、疾患再発の早期発見に役立ち、治療反応性をより正確に評価し、患者を特定し、患者の転帰を改善し、カスタマイズされた治療計画を強化することによって、個別化された治療計画の指針となる。

微小残存病変(MRD)検査の市場動向:
世界中で癌の有病率が増加していることが、市場成長を促進する主な要因の1つである。MRD検査は、残存がん細胞を検出するために広く使用されている高感度技術であり、疾患の再発を早期に示唆し、個別化された治療計画の指針となる。これに伴い、造血組織または免疫系の細胞から始まる血液がんにおいて、診断およびモニタリングツールとしてMRD検査が広く採用されていることが、市場の成長を後押ししている。さらに、カスタマイズされた治療計画やモニタリングを可能にする個別化医療に対する消費者の嗜好の変化が、もう一つの成長促進要因として作用している。これとは別に、人工知能(AI)をMRD検査に統合することで、パターンの特定、再発の可能性の予測、診断の正確性と有効性の向上、臨床医が患者のケアについてより多くの情報に基づいた意思決定を行うのに役立ち、市場成長に弾みをつけている。さらに、デオキシリボ核酸(DNA)またはリボ核酸(RNA)の塩基配列を決定し、疾患に関連する遺伝的変異を研究するためのNGS技術の採用が増加していることも、市場に明るい展望をもたらしている。さらに、体内でがんを引き起こす可能性のある発がん性物質の存在を特定することの重要性に対する人々の意識の高まりが、市場の成長を後押ししている。その他にも、医療業界の著しい成長、広範な研究開発(R&D)活動、MRD検査プログラム分野への投資の増加などが、市場の成長を促進すると予想される。

主な市場セグメンテーション
IMARC Groupは、世界の微小残存病変(MRD)検査市場の各セグメントにおける主要動向の分析と、2024年から2032年にかけての世界、地域、国レベルでの予測を提供しています。当レポートでは、市場を技術、用途、エンドユーザーに基づいて分類しています。

技術の洞察

フローサイトメトリー
ポリメラーゼ連鎖反応(PCR)
次世代シーケンサー(NGS)
その他

この調査レポートは、最小残存病変(MRD)検査市場を技術別に詳細に分類・分析しています。これにはフローサイトメトリー、ポリメラーゼ連鎖反応(PCR)、次世代シーケンシング(NGS)、その他が含まれる。報告書によると、ポリメラーゼ連鎖反応(PCR)が最大のセグメントを占めた。

アプリケーションの洞察

血液悪性腫瘍
白血病
リンパ腫
固形腫瘍

本レポートでは、最小残存病変(MRD)検査市場を用途別に詳細に分類・分析している。これには血液悪性腫瘍(白血病およびリンパ腫)と固形腫瘍が含まれる。報告書によると、血液悪性腫瘍(白血病とリンパ腫)が最大の市場シェアを占めている。

エンドユーザーの洞察

病院および専門クリニック
診断研究所
学術・研究機関
その他

この調査レポートは、最小残存病変(MRD)検査市場をエンドユーザー別に詳細に分類・分析しています。これには、病院・専門クリニック、診断ラボ、学術・研究機関、その他が含まれる。報告書によると、病院と専門クリニックが最大のセグメントを占めている。

地域別インサイト

北米
米国
カナダ
アジア太平洋
中国
日本
インド
韓国
オーストラリア
インドネシア
その他
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
ロシア
その他
ラテンアメリカ
ブラジル
メキシコ
その他
中東・アフリカ

また、北米(米国、カナダ)、欧州(ドイツ、フランス、英国、イタリア、スペイン、ロシア、その他)、アジア太平洋(中国、日本、インド、韓国、オーストラリア、インドネシア、その他)、中南米(ブラジル、メキシコ、その他)、中東・アフリカを含む主要地域市場についても包括的な分析を行っている。報告書によると、北米は最小残存病変(MRD)検査の最大市場であった。北米の微小残存病変(MRD)検査市場を牽引する要因としては、癌の有病率の増加、医療業界の著しい成長、広範な研究開発(R&D)活動などが挙げられる。

競合情勢:
本レポートでは、世界の微小残存病変(MRD)検査市場における競争環境についても包括的に分析している。市場構造、主要プレーヤーによる市場シェア、プレーヤーのポジショニング、トップ勝ち抜き戦略、競合ダッシュボード、企業評価象限などの競合分析が本レポートで取り上げられています。また、主要企業の詳細プロフィールも掲載しています。対象となる企業には、Adaptive Biotechnologies Corporation、Arup Laboratories Inc.、Bio-Rad Laboratories Inc.、Guardant Health、Invivoscribe Inc.、Natera Inc.、NeoGenomics Laboratories Inc.、Sysmex Corporationなどがあります。

本レポートで扱う主な質問
世界の最小残存病変(MRD)検査市場はこれまでどのように推移してきたか?
世界の最小残存病変(MRD)検査市場における促進要因、阻害要因、機会は何か?
各駆動因子、阻害因子、機会が世界の最小残存病変(MRD)検査市場に与える影響は?
主要な地域市場は?
最も魅力的な最小残存病変(MRD)検査市場はどの国か?
技術に基づく市場の内訳は?
最小残存病変(MRD)検査市場で最も魅力的な技術はどれか?
アプリケーションに基づく市場の内訳は?
最小残存病変(MRD)検査市場で最も魅力的なアプリケーションはどれか?
エンドユーザーに基づく市場の内訳は?
最小残存病変(MRD)検査市場で最も魅力的なエンドユーザーはどこか?
世界の最小残存病変(MRD)検査市場の競争構造は?
世界の最小残存病変(MRD)検査市場における主要プレイヤー/企業は?

ページTOPに戻る


目次

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Minimal Residual Disease (MRD) Testing Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Technology
6.1 Flow Cytometry
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Polymerase Chain Reaction (PCR)
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Next Generation Sequencing (NGS)
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Application
7.1 Hematological Malignancy
7.1.1 Market Trends
7.1.2 Key Segments
7.1.2.1 Leukemia
7.1.2.2 Lymphoma
7.1.3 Market Forecast
7.2 Solid Tumors
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by End User
8.1 Hospitals and Speciality Clinics
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Diagnostic Laboratories
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Academic and Research Institutes
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Adaptive Biotechnologies Corporation
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.2 Arup Laboratories Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 SWOT Analysis
14.3.3 Bio-Rad Laboratories Inc.
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Guardant Health
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.5 Invivoscribe Inc.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.6 Natera Inc.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.7 NeoGenomics Laboratories Inc.
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.8 Sysmex Corporation
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis

List of Figures
Figure 1: Global: Minimal Residual Disease Testing Market: Major Drivers and Challenges
Figure 2: Global: Minimal Residual Disease Testing Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Minimal Residual Disease Testing Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Minimal Residual Disease Testing Market: Breakup by Technology (in %), 2023
Figure 5: Global: Minimal Residual Disease Testing Market: Breakup by Application (in %), 2023
Figure 6: Global: Minimal Residual Disease Testing Market: Breakup by End User (in %), 2023
Figure 7: Global: Minimal Residual Disease Testing Market: Breakup by Region (in %), 2023
Figure 8: Global: Minimal Residual Disease Testing (Flow Cytometry) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Minimal Residual Disease Testing (Flow Cytometry) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Minimal Residual Disease Testing (Polymerase Chain Reaction (PCR)) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Minimal Residual Disease Testing (Polymerase Chain Reaction (PCR)) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Minimal Residual Disease Testing (Next Generation Sequencing (NGS)) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Minimal Residual Disease Testing (Next Generation Sequencing (NGS)) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Minimal Residual Disease Testing (Other Technologies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Minimal Residual Disease Testing (Other Technologies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Minimal Residual Disease Testing (Hematological Malignancy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Minimal Residual Disease Testing (Hematological Malignancy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Minimal Residual Disease Testing (Solid Tumors) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Minimal Residual Disease Testing (Solid Tumors) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Minimal Residual Disease Testing (Hospitals and Speciality Clinics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Minimal Residual Disease Testing (Hospitals and Speciality Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Minimal Residual Disease Testing (Diagnostic Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Minimal Residual Disease Testing (Diagnostic Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Minimal Residual Disease Testing (Academic and Research Institutes) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Minimal Residual Disease Testing (Academic and Research Institutes) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Global: Minimal Residual Disease Testing (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Global: Minimal Residual Disease Testing (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: North America: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: North America: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: United States: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: United States: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: Canada: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: Canada: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Asia-Pacific: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Asia-Pacific: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: China: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: China: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: Japan: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: Japan: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: India: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: India: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: South Korea: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: South Korea: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: Australia: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: Australia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Indonesia: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Indonesia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: Others: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: Europe: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: Europe: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: Germany: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: Germany: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: France: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: France: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: United Kingdom: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: United Kingdom: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: Italy: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Italy: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: Spain: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: Spain: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Russia: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Russia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Others: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Latin America: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Latin America: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: Brazil: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: Brazil: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Mexico: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Mexico: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: Others: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 73: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 74: Middle East and Africa: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 75: Middle East and Africa: Minimal Residual Disease Testing Market: Breakup by Country (in %), 2023
Figure 76: Middle East and Africa: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 77: Global: Minimal Residual Disease Testing Industry: Drivers, Restraints, and Opportunities
Figure 78: Global: Minimal Residual Disease Testing Industry: Value Chain Analysis
Figure 79: Global: Minimal Residual Disease Testing Industry: Porter's Five Forces Analysis
List of Tables
Table 1: Global: Minimal Residual Disease Testing Market: Key Industry Highlights, 2023 & 2032
Table 2: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Technology (in Million US$), 2024-2032
Table 3: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Application (in Million US$), 2024-2032
Table 4: Global: Minimal Residual Disease Testing Market Forecast: Breakup by End User (in Million US$), 2024-2032
Table 5: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Minimal Residual Disease Testing Market: Competitive Structure
Table 7: Global: Minimal Residual Disease Testing Market: Key Players

 

ページTOPに戻る


 

Summary

The global minimal residual disease (MRD) testing market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.1 Billion by 2032, exhibiting a growth rate (CAGR) of 10.21% during 2024-2032. Significant growth in the healthcare industry, extensive research and development (R&D) activities and rapid technological advancements represent some of the key factors driving the market.

Minimal residual disease (MRD) testing is a medical test used to detect and monitor small amounts of cancer cells that may remain in a patient's body after undergoing cancer treatment. It is widely used to test a variety of different types of cancer, such as leukemia, lymphoma, multiple myeloma, and some solid tumors. MRD testing uses highly sensitive methods, including cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS). It is an important medical test for monitoring cancer patients and helping doctors to make more informed treatment decisions. MRD testing helps in the early detection of disease recurrence, providing a more accurate assessment of treatment response and guiding personalized treatment planning by identifying patients, improving patient outcomes, and enhancing customized treatment planning.

Minimal Residual Disease (MRD) Testing Market Trends:
The increasing prevalence of cancer across the globe is one of the key factors driving the market growth. MRD testing is a highly sensitive technique that is widely used to detect residual cancer cells, which helps in an early indication of disease recurrence and helps guide personalized treatment planning. In line with this, the widespread adoption of MRD testing as a diagnostic and monitoring tool in hematological cancers that begin in blood-forming tissues or the cell of the immune system is favoring the market growth. Moreover, the shifting consumer preference toward personalized medicine that allows customized treatment planning and monitoring are acting as another growth-inducing factor. Apart from this, the integration of artificial intelligence (AI) with MRD testing that helps to identify patterns, predict the likelihood of recurrence, improve the accuracy and effectiveness of diagnosis, and help clinicians to make more informed decisions about patient care, is providing an impetus to the market growth. Additionally, the increasing adoption of NGS technology to determine the sequence of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) to study the genetic variations associated with the disease is creating a positive outlook for the market. Furthermore, growing awareness among people about the importance of identifying the presence of carcinogenic substances that can cause cancer in the body is propelling the market growth. Other factors, including significant growth in the healthcare industry, extensive research and development (R&D) activities, and increasing investments in the field of MRD testing programs, are anticipated to drive the market growth.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global minimal residual disease (MRD) testing market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on technology, application, and end user.

Technology Insights:

Flow Cytometry
Polymerase Chain Reaction (PCR)
Next Generation Sequencing (NGS)
Others

The report has provided a detailed breakup and analysis of the minimal residual disease (MRD) testing market based on the technology. This includes flow cytometry, polymerase chain reaction (PCR), next generation sequencing (NGS) and others. According to the report, polymerase chain reaction (PCR) represented the largest segment.

Application Insights:

Hematological Malignancy
Leukemia
Lymphoma
Solid Tumors

A detailed breakup and analysis of the minimal residual disease (MRD) testing market based on the application has also been provided in the report. This includes hematological malignancy (leukemia and lymphoma) and solid tumors. According to the report, hematological malignancy (leukemia and lymphoma) accounted for the largest market share.

End User Insights:

Hospitals and Speciality Clinics
Diagnostic Laboratories
Academic and Research Institutes
Others

The report has provided a detailed breakup and analysis of the minimal residual disease (MRD) testing market based on the end user. This includes hospitals and speciality clinics, diagnostic laboratories, academic and research institutes, and others. According to the report, hospitals and speciality clinics represented the largest segment.

Regional Insights:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for minimal residual disease (MRD) testing. Some of the factors driving the North America minimal residual disease (MRD) testing market included the increasing prevalence of cancer, significant growth in the healthcare industry, and extensive research and development (R&D) activities.

Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global minimal residual disease (MRD) testing market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Adaptive Biotechnologies Corporation, Arup Laboratories Inc., Bio-Rad Laboratories Inc., Guardant Health, Invivoscribe Inc., Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, etc.

Key Questions Answered in This Report:
How has the global minimal residual disease (MRD) testing market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global minimal residual disease (MRD) testing market?
What is the impact of each driver, restraint, and opportunity on the global minimal residual disease (MRD) testing market?
What are the key regional markets?
Which countries represent the most attractive minimal residual disease (MRD) testing market?
What is the breakup of the market based on technology?
Which is the most attractive technology in the minimal residual disease (MRD) testing market?
What is the breakup of the market based on the application?
Which is the most attractive application in the minimal residual disease (MRD) testing market?
What is the breakup of the market based on the end user?
Which is the most attractive end user in the minimal residual disease (MRD) testing market?
What is the competitive structure of the global minimal residual disease (MRD) testing market?
Who are the key players/companies in the global minimal residual disease (MRD) testing market?



ページTOPに戻る


Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Minimal Residual Disease (MRD) Testing Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Technology
6.1 Flow Cytometry
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Polymerase Chain Reaction (PCR)
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Next Generation Sequencing (NGS)
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Application
7.1 Hematological Malignancy
7.1.1 Market Trends
7.1.2 Key Segments
7.1.2.1 Leukemia
7.1.2.2 Lymphoma
7.1.3 Market Forecast
7.2 Solid Tumors
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by End User
8.1 Hospitals and Speciality Clinics
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Diagnostic Laboratories
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Academic and Research Institutes
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Adaptive Biotechnologies Corporation
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.2 Arup Laboratories Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 SWOT Analysis
14.3.3 Bio-Rad Laboratories Inc.
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Guardant Health
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.5 Invivoscribe Inc.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.6 Natera Inc.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.7 NeoGenomics Laboratories Inc.
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.8 Sysmex Corporation
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis

List of Figures
Figure 1: Global: Minimal Residual Disease Testing Market: Major Drivers and Challenges
Figure 2: Global: Minimal Residual Disease Testing Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Minimal Residual Disease Testing Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Minimal Residual Disease Testing Market: Breakup by Technology (in %), 2023
Figure 5: Global: Minimal Residual Disease Testing Market: Breakup by Application (in %), 2023
Figure 6: Global: Minimal Residual Disease Testing Market: Breakup by End User (in %), 2023
Figure 7: Global: Minimal Residual Disease Testing Market: Breakup by Region (in %), 2023
Figure 8: Global: Minimal Residual Disease Testing (Flow Cytometry) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Minimal Residual Disease Testing (Flow Cytometry) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Minimal Residual Disease Testing (Polymerase Chain Reaction (PCR)) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Minimal Residual Disease Testing (Polymerase Chain Reaction (PCR)) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Minimal Residual Disease Testing (Next Generation Sequencing (NGS)) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Minimal Residual Disease Testing (Next Generation Sequencing (NGS)) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Minimal Residual Disease Testing (Other Technologies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Minimal Residual Disease Testing (Other Technologies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Minimal Residual Disease Testing (Hematological Malignancy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Minimal Residual Disease Testing (Hematological Malignancy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Minimal Residual Disease Testing (Solid Tumors) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Minimal Residual Disease Testing (Solid Tumors) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Minimal Residual Disease Testing (Hospitals and Speciality Clinics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Minimal Residual Disease Testing (Hospitals and Speciality Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Minimal Residual Disease Testing (Diagnostic Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Minimal Residual Disease Testing (Diagnostic Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Minimal Residual Disease Testing (Academic and Research Institutes) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Minimal Residual Disease Testing (Academic and Research Institutes) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Global: Minimal Residual Disease Testing (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Global: Minimal Residual Disease Testing (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: North America: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: North America: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: United States: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: United States: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: Canada: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: Canada: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Asia-Pacific: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Asia-Pacific: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: China: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: China: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: Japan: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: Japan: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: India: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: India: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: South Korea: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: South Korea: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: Australia: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: Australia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Indonesia: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Indonesia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: Others: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: Europe: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: Europe: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: Germany: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: Germany: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: France: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: France: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: United Kingdom: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: United Kingdom: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: Italy: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Italy: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: Spain: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: Spain: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Russia: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Russia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Others: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Latin America: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Latin America: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: Brazil: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: Brazil: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Mexico: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Mexico: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: Others: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 73: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 74: Middle East and Africa: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 75: Middle East and Africa: Minimal Residual Disease Testing Market: Breakup by Country (in %), 2023
Figure 76: Middle East and Africa: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 77: Global: Minimal Residual Disease Testing Industry: Drivers, Restraints, and Opportunities
Figure 78: Global: Minimal Residual Disease Testing Industry: Value Chain Analysis
Figure 79: Global: Minimal Residual Disease Testing Industry: Porter's Five Forces Analysis
List of Tables
Table 1: Global: Minimal Residual Disease Testing Market: Key Industry Highlights, 2023 & 2032
Table 2: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Technology (in Million US$), 2024-2032
Table 3: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Application (in Million US$), 2024-2032
Table 4: Global: Minimal Residual Disease Testing Market Forecast: Breakup by End User (in Million US$), 2024-2032
Table 5: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Minimal Residual Disease Testing Market: Competitive Structure
Table 7: Global: Minimal Residual Disease Testing Market: Key Players

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

IMARC Services Private Limited.社の医療分野での最新刊レポート

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


IMARC Services Private Limited.社はどのような調査会社ですか?


インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/26 10:26

155.24 円

162.59 円

197.14 円

ページTOPに戻る